On May, 11 The EPS for ADMA Biologics, Inc. (ADMA) Expected At $-0.27

May 3, 2018 - By Sarah Harris

ADMA Biologics, Inc. (NASDAQ:ADMA) Corporate Logo
Big Money Sentiment increased to 3 in 2017 Q4. It has change of 1.86, from 2017Q3’s 1.14. The ratio is positive due to ADMA Biologics, Inc. positioning: 4 sold and 2 reduced. 8 funds took holdings and 10 increased holdings. Investors holded 7.02 million in 2017Q3 but now own 15.53 million shares or 121.29% more.
Moreover, Virtu Fin Lc has 0% invested in ADMA Biologics, Inc. (NASDAQ:ADMA) for 23,188 shs. Geode Cap Limited Liability Company accumulated 112,000 shs or 0% of the stock. Blackrock has 0% invested in ADMA Biologics, Inc. (NASDAQ:ADMA). Prelude Ltd Liability has invested 0.01% of its capital in ADMA Biologics, Inc. (NASDAQ:ADMA). Broadfin Capital holds 0.58% of its capital in ADMA Biologics, Inc. (NASDAQ:ADMA) for 1.10M shs. 3.61 million are owned by Aisling Limited Liability. Northern Tru Corporation holds 0% or 31,405 shs. Wells Fargo & Mn reported 7,000 shs stake. Consonance Capital Ltd Partnership holds 3.37M shs or 0.98% of its capital. 683 Management Ltd reported 0.26% in ADMA Biologics, Inc. (NASDAQ:ADMA). Royal State Bank Of Canada has invested 0% in ADMA Biologics, Inc. (NASDAQ:ADMA). Perceptive Advsr Ltd holds 3.82M shs. Vanguard, a Pennsylvania-based fund reported 639,506 shs. Morgan Stanley has invested 0% in ADMA Biologics, Inc. (NASDAQ:ADMA). Goldman Sachs Group Inc holds 0% in ADMA Biologics, Inc. (NASDAQ:ADMA) or 30,520 shs.

ADMA Biologics, Inc. (NASDAQ:ADMA)’s earnings report is expected on May, 11., according to Zacks. Analysts predict 47.06 % diference or $-0.27 from the $-0.51 EPS from 2017. Analysts at Wall Street see ADMA Biologics, Inc.’s 12.50 % negative EPS growth compared to $-0.24 EPS for previous quarter. ADMA is touching $4.72 during the last trading session, after decreased 1.05%.ADMA Biologics, Inc. has volume of 53,458 shares. Since May 3, 2017 ADMA has risen 0.20% and is uptrending. ADMA underperformed by 11.35% the S&P 500.

ADMA Biologics, Inc., a biopharmaceutical company, develops, makes, and markets specialty plasma biologics for the treatment of immune deficiencies and infectious diseases.The firm is worth $213.90 million. The Company’s lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease.Last it reported negative earnings. The firm also operates source plasma collection facilities in Norcross and Marietta, Georgia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: